Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ross C Donehower

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Current Oncology Reports|December 6, 2001
Evolving therapies: farnesyltransferase inhibitorsW Thomas Purcell, Ross C Donehower
The Cochrane Database of Systematic Reviews|February 18, 2011
Interventions for preventing neuropathy caused by cisplatin and related compoundsJames W Albers, Vinay Chaudhry, Guido Cavaletti, et al.
The Cochrane Database of Systematic Reviews|April 2, 2014
Interventions for preventing neuropathy caused by cisplatin and related compoundsJames W Albers, Vinay Chaudhry, Guido Cavaletti, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 15, 2016
Effects of the leucovorin shortage: Pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in patients with resectable colon or metastatic colorectal cancerBrandon R Shank, Amy H Seung, Katharine Kinsman, et al.
Pharmacotherapy|January 27, 2004
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic studyMichelle A Rudek, Ross C Donehower, Paul Statkevich, et al.
Investigational New Drugs|June 11, 2003
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancerE Claire Dees, Eric K Rowinsky, Dennis A Noe, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 26, 2007
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasmaJing Li, Ming Zhao, Antonio Jimeno, et al.
Journal of the National Cancer Institute|December 19, 2002
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001Sharyn D Baker, Jaap Verweij, Eric K Rowinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumorsAntonio Jimeno, Jing Li, Wells A Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II study of erlotinib in patients with advanced biliary cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Current Oncology Reports|December 6, 2001
Evolving therapies: farnesyltransferase inhibitorsW Thomas Purcell, Ross C Donehower
The Cochrane Database of Systematic Reviews|February 18, 2011
Interventions for preventing neuropathy caused by cisplatin and related compoundsJames W Albers, Vinay Chaudhry, Guido Cavaletti, et al.
The Cochrane Database of Systematic Reviews|April 2, 2014
Interventions for preventing neuropathy caused by cisplatin and related compoundsJames W Albers, Vinay Chaudhry, Guido Cavaletti, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 15, 2016
Effects of the leucovorin shortage: Pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in patients with resectable colon or metastatic colorectal cancerBrandon R Shank, Amy H Seung, Katharine Kinsman, et al.
Pharmacotherapy|January 27, 2004
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic studyMichelle A Rudek, Ross C Donehower, Paul Statkevich, et al.
Investigational New Drugs|June 11, 2003
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancerE Claire Dees, Eric K Rowinsky, Dennis A Noe, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 26, 2007
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasmaJing Li, Ming Zhao, Antonio Jimeno, et al.
Journal of the National Cancer Institute|December 19, 2002
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001Sharyn D Baker, Jaap Verweij, Eric K Rowinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumorsAntonio Jimeno, Jing Li, Wells A Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II study of erlotinib in patients with advanced biliary cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.
Pageof 5